Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Verastem Inc (VSTM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 239,323
  • Shares Outstanding, K 73,865
  • Annual Sales, $ 26,720 K
  • Annual Income, $ -72,430 K
  • 60-Month Beta 3.04
  • Price/Sales 9.62
  • Price/Cash Flow N/A
  • Price/Book 2.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.49
  • Number of Estimates 2
  • High Estimate -0.47
  • Low Estimate -0.50
  • Prior Year -0.41
  • Growth Rate Est. (year over year) -19.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.61 +24.14%
on 03/07/19
3.66 -11.48%
on 03/21/19
+0.04 (+1.25%)
since 02/22/19
3-Month
2.61 +24.14%
on 03/07/19
4.25 -23.76%
on 01/09/19
+0.01 (+0.31%)
since 12/21/18
52-Week
2.61 +24.14%
on 03/07/19
10.35 -68.70%
on 09/04/18
+0.12 (+3.85%)
since 03/22/18

Most Recent Stories

More News
Verastem (VSTM) Reports Q4 Loss, Misses Revenue Estimates

Verastem (VSTM) delivered earnings and revenue surprises of 31.48% and -78.25%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

VSTM : 3.24 (-6.90%)
Verastem Oncology to Present at Upcoming Investor Conferences

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients,...

VSTM : 3.24 (-6.90%)
Do Options Traders Know Something About Verastem (VSTM) Stock We Don't?

Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

VSTM : 3.24 (-6.90%)
Verastem Oncology Presents Further COPIKTRA(TM) (Duvelisib) Data at the 23rd Annual International Congress on Hematologic Malignancies

--DUO(TM) Crossover Extension Study Demonstrates 77% ORR and Median PFS of 15 Months in Patients with Relapsed or Refractory CLL/SLL Who Had Experienced Disease Progression Following Ofatumumab Monotherapy;...

VSTM : 3.24 (-6.90%)
Verastem Oncology Presents Phase 3 DUO(TM) Data Evaluating COPIKTRA(TM) (Duvelisib) in Patients with CLL/SLL Who Have Progressed Following Two Prior Lines of Therapy

--COPIKTRA Demonstrates Progression-Free Survival of 16.4 Months and an Overall Response Rate of 78% in Adult Patients with CLL/SLL After At Least Two Prior Therapies

VSTM : 3.24 (-6.90%)
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc.(Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced...

VSTM : 3.24 (-6.90%)
Verastem Oncology to Announce Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update on March 12, 2019

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality...

VSTM : 3.24 (-6.90%)
Verastem Oncology to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today...

VSTM : 3.24 (-6.90%)
Verastem Oncology Announces Key Management Appointments

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality...

PZRX : 0.28 (-9.68%)
VSTM : 3.24 (-6.90%)
Verastem Oncology Announces Publication of the Phase 2 DYNAMO Study Results in Indolent Non-Hodgkin Lymphoma in the Journal of Clinical Oncology

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality...

VSTM : 3.24 (-6.90%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Steady.

See More Share

Trade VSTM with:

Business Summary

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib...

See More

Key Turning Points

2nd Resistance Point 3.66
1st Resistance Point 3.45
Last Price 3.24
1st Support Level 3.11
2nd Support Level 2.99

See More

52-Week High 10.35
Fibonacci 61.8% 7.39
Fibonacci 50% 6.48
Fibonacci 38.2% 5.57
Last Price 3.24
52-Week Low 2.61

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar